Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19152
Title: Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
Austin Authors: Ghisi, Margherita;Kats, Lev;Masson, Frederic;Li, Jason;Kratina, Tobias;Vidacs, Eva;Gilan, Omer;Doyle, Maria A;Newbold, Andrea;Bolden, Jessica E;Fairfax, Kirsten A;de Graaf, Carolyn A;Firth, Matthew;Zuber, Johannes;Dickins, Ross A;Corcoran, Lynn M;Dawson, Mark A;Belz, Gabrielle T;Johnstone, Ricky W
Affiliation: School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 3010 Victoria, Australia
Cancer Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Dr. Bohr-Gasse 7, 1030 Vienna, Austria
Australian Centre for Blood Diseases, Monash University, Melbourne, 3004 Victoria, Australia
Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, 3002 Victoria, Australia
Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Bioinformatics Core, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria, Australia
Research Computing Facility, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria, Australia
Molecular Medicine Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, Australia
Issue Date: 11-Jul-2016
metadata.dc.date: 2016-06-30
Publication information: Cancer cell 2016; 30(1): 59-74
Abstract: E proteins and their antagonists, the Id proteins, are transcriptional regulators important for normal hematopoiesis. We found that Id2 acts as a key regulator of leukemia stem cell (LSC) potential in MLL-rearranged acute myeloid leukemia (AML). Low endogenous Id2 expression is associated with LSC enrichment while Id2 overexpression impairs MLL-AF9-leukemia initiation and growth. Importantly, MLL-AF9 itself controls the E-protein pathway by suppressing Id2 while directly activating E2-2 expression, and E2-2 depletion phenocopies Id2 overexpression in MLL-AF9-AML cells. Remarkably, Id2 tumor-suppressive function is conserved in t(8;21) AML. Low expression of Id2 and its associated gene signature are associated with poor prognosis in MLL-rearranged and t(8;21) AML patients, identifying the Id2/E-protein axis as a promising new therapeutic target in AML.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19152
DOI: 10.1016/j.ccell.2016.05.019
PubMed URL: 27374225
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.